Breast MRI developer Caprius has received three letters of intent for joint ventures utilizing the Wilmington, MA-based company’s Aurora scanner, which is the only dedicated MRI breast imaging system to have received Food and Drug Administration
Breast MRI developer Caprius has received three letters of intent for joint ventures utilizing the Wilmington, MA-based companys Aurora scanner, which is the only dedicated MRI breast imaging system to have received Food and Drug Administration 510(k) clearance. The joint ventures partners would be located in New York City, Columbus, OH, and Knoxville, TN, and would be similar to other joint ventures currently in operation in sites such as Magee Womens Hospital and Englewood Hospital and Medical Center, according to Caprius.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.